Benjamin Cravatt, Ph.D. is currently a professor and chair of the Department of Chemical Physiology and co-director of the Center for Physiological Proteomics at The Scripps Research Institute. Dr. Cravatt is a nationally recognized leader in the fields of bioorganic chemistry and enzymology. His research group has a broad range of experimental expertise, ranging from synthetic chemistry to molecular biology to mammalian physiology. His group has obtained fundamental insights into the chemical, biochemical, and physiological workings of several important mammalian serine hydrolases, including enzymes involved in the neurobiology of pain and in proteases associated with tumor progression.
Dr. Cravatt’s research has won a number of awards. His honors include a Top 100 Young Innovator award from Technology Review, a Promega Young Life Scientist Award from the American Society for Cell Biology, and the Eli Lilly Award in Biological Chemistry from the American Chemical Society. He is a co-founder and member of the scientific advisory board of San Diego-based ActivX Biosciences.
Dr. Cravatt received his B.S. in Biological Sciences and B.A. in History from Stanford University in 1992. He received his Ph.D. in macromolecular and cellular structure and chemistry from The Scripps Research Institute.
Where should any financial technology startup live? We’re here to urge you to look no further, and seriously consider Boston. Boston is and will remain the perfect home for FinTech startups today and for years to come. Read on to learn why we’re so confident.